This study is a randomized, open-label, controlled, phase III study to evaluate the efficacy and safety of HS-20089 versus investigator's choice of chemotherapy in patients with platinum-resistant recurrent epithelial ovarian cancer.
Voluntary participation and written informed consent.
18 years and older, female.
Pathologically diagnosed epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer.
Patients must have platinum-resistant disease
Prior treated with TOP1 inhibitors or ADCs with TOP1 inhibitors as payload.
Previous or co-existing malignancies.
Uncontrolled pleural effusion, pericardial effusion, or abdominal effusion requiring clinical intervention.
Received systemic anticancer treatments 4 weeks prior to the initiation of the study treatment.